



October 13, 2015

## **ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results**

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Tuesday, October 27, 2015, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2015. Management also will provide an update on the Company.

To access the live call by phone, dial 913-905-3226; the conference ID is 9613638. The call also may be accessed through the Investors section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the live webcast, a replay of the call will be available at the same location through November 10, 2015.

### **About ImmunoGen, Inc.**

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche's Kadcyla<sup>®</sup> is the first marketed product with ImmunoGen's ADC technology. More information about the Company can be found at [www.immunogen.com](http://www.immunogen.com).

Kadcyla<sup>®</sup> is a registered trademark of Genentech, a member of the Roche Group.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20151013005239/en/>

For Investors & Media:  
ImmunoGen, Inc.  
Carol Hausner, 781-895-0600  
[info@immunogen.com](mailto:info@immunogen.com)

Source: ImmunoGen, Inc.

News Provided by Acquire Media